Tag: Lebrikizumab

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Lebrikizumab

Lilly's new eczema drug scores in late-stage studies | BioPharma Dive

Added to Collection on: 2021-08-16 16:18:45

Tags for this article:

Health sciences
Health care
Health
Monoclonal antibodies
Autoimmune diseases
Sanofi
CAC 40
Regeneron Pharmaceuticals
Lebrikizumab
Pharmaceutical industry
Dupilumab
Eli Lilly

Click the tags to see associated articles and topics

View Article Details
Leo Pharma's FDA nod adds a challenger to Dupixent's dominance in eczema - MedCity News

Added to Collection on: 2021-12-28 17:18:49

Tags for this article:

Health sciences
Life Sciences
Health care
Monoclonal antibodies
Type I hypersensitivity
Tralokinumab
Dupilumab
Atopic dermatitis
Dermatitis
Regeneron Pharmaceuticals
Sanofi
Lebrikizumab
United States
Leo Pharma

Click the tags to see associated articles and topics

View Article Details
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal ...

Added to Collection on: 2022-03-26 22:45:04

Tags for this article:

Medical specialties
Immunology
Clinical medicine
Type I hypersensitivity
Monoclonal antibodies
Lebrikizumab
Autoimmune diseases
Type 2 inflammation
Eli Lilly and Company
EASI
Atopic dermatitis
Eczema Area and Severity Index
New York

Click the tags to see associated articles and topics

View Article Details
Lilly Poised to Take on Competitors in Atopic Dermatitis | BioSpace

Added to Collection on: 2022-04-12 19:23:04

Tags for this article:

Medical specialties
Monoclonal antibodies
Immunology
Type I hypersensitivity
Organ systems
Corticosteroids
Breakthrough therapy
Dupilumab
Sanofi
Lebrikizumab
Atopic dermatitis
Dermatitis
Eli Lilly

Click the tags to see associated articles and topics

View Article Details
Managing Atopic Dermatitis with Lebrikizumab | CCID - Dove Medical Press

Added to Collection on: 2022-06-07 13:55:25

Tags for this article:

Monoclonal antibodies
Medical specialties
Organ systems
Immunology
Lebrikizumab
Dupilumab
Atopic dermatitis
Upadacitinib
Immunoglobulin E
Idiopathic pulmonary fibrosis
Dermatitis
Tralokinumab

Click the tags to see associated articles and topics

View Article Details
Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

Added to Collection on: 2024-06-21 21:11:48

Tags for this article:

Immunosuppressants
Lebrikizumab
Atopic dermatitis
EASI
Almirall
Dermatitis
Eli Lilly and Company
Chicago

Click the tags to see associated articles and topics

View Article Details
Lilly Announces FDA Approval for Lebrikizumab-lbkz of Moderate to Severe Atopic Dermatitis

Added to Collection on: 2024-09-16 16:31:35

Tags for this article:

Immunosuppressants
Corticosteroids
Autoimmune diseases
Lebrikizumab
Atopic dermatitis
Eli Lilly and Company
Itch
Dermatitis
Topical steroid
Placebo

Click the tags to see associated articles and topics

View Article Details
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says ...

Added to Collection on: 2024-09-25 17:51:55

Tags for this article:

Amgen
MariTide
Atopic dermatitis
Lebrikizumab
Dupilumab
Goldman Sachs
Dermatitis
Eli Lilly and Company
Amgen Inc.

Click the tags to see associated articles and topics

View Article Details
The Latest in Dermatology With James Del Rosso, DO: Part 2

Added to Collection on: 2024-10-25 17:47:31

Tags for this article:

Autoimmune diseases
Psoriasis
Monoclonal antibodies
Janus kinase inhibitor
Atopic dermatitis
Upadacitinib
Tralokinumab
Hidradenitis suppurativa
Lebrikizumab
Dupilumab
Psoriatic arthritis
Dermatitis
Secukinumab

Click the tags to see associated articles and topics

View Article Details
Drug Review: Lebrikizumab-lbkz Demonstrates Improvement in Atopic Dermatitis

Added to Collection on: 2024-11-25 17:01:50

Tags for this article:

Type I hypersensitivity
Immunosuppressants
Lebrikizumab
Corticosteroids
Atopic dermatitis
Type 2 inflammation
Dermatitis
Topical steroid
Eli Lilly and Company
Atopy

Click the tags to see associated articles and topics

View Article Details